1. Pink Sheet

Curis/Genentech Report Positive Phase II Results For Vismodegib

 
• By The Pink Sheet Daily

Curis and its partner, Roche's Genentech, plan a 2011 filing for basal cell carcinoma drug vismodegib after announcing positive mid-stage results.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Pink Sheet